TP53 and sarcoma: Another study retrospectively reviewed 19 cases of patients with advanced sarcoma treated with VEGFR inhibition and discovered that the PFS of patients with TP53 mutations was significantly greater than TP53 wild-type tumors with the median PFS of 208 versus 136 days, respectively [P=0.036, hazards ratio 0.38 (95% confidence interval 0.09-0.83)] (76).